Last updated on December 2018

Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)


Brief description of study

This study aims to evaluate safety and efficacy of nivolumab (anti-PD-1 antibody), which is approved as tertiary therapy, and neoadjuvant short-term limited local radiotherapy in patients with unresectable recurrent gastric cancer who progressed (SD or PD) after standard treatment (primary and secondary chemotherapy) and have more than one lesion assessable in diagnostic imaging (one lesion must be >=2cm).

Detailed Study Description

In patients with unresectable recurrent gastric cancer who progressed (SD or PD) after standard treatment (primary and secondary chemotherapy) and have more than one lesion assessable in diagnostic imaging (one lesion must be >=2cm), localized short-term radiotherapy of 22.5 Gy/5 fractions/5 days will be applied to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation (Day 1-5). Nivolumab will be administered starting from Day 15-22 at a dose of 3 mg/kg (body wait) every 2 weeks to a total of 6 courses (end of intervention).

The patients will be observed up to Day 18014 and evaluated on Day 18014 (end of study).

Clinical Study Identifier: NCT03453164

Contact Investigators or Research Sites near you

Start Over

Koji Kono, M.D., Ph.D.

Fukushima Medical University Hospital
Fukushima, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.